Physician profile
Christopher M Lee
NPI 1043266810
$137,670.49
in general payments reported to CMS, 2019-2025
41 companies · $16K in 2025
The $16K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,168 · 2020: $17K · 2021: $9,901 · 2022: $22K · 2023: $30K · 2024: $37K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Honoraria: $27K · Consulting Fee: $19K · Travel and Lodging: $3,208 · Food and Beverage: $3,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,760.00 |
| Honoraria | $26,975.00 |
| Consulting Fee | $19,225.00 |
| Travel and Lodging | $3,208.31 |
| Food and Beverage | $3,169.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71,688.59 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $63,066.86 | 2022-2025 | Prolaris, Myrisk |
| Astrazeneca Pharmaceuticals Lp | $497.68 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Telix Pharmaceuticals | $295.94 | 2023-2025 | Illuccix |
| Janssen Biotech, INC. | $170.17 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $169.23 | 2024-2025 | |
| Galvanize Therapeutics, INC | $145.00 | 2023 | Aliya System |
| Dendreon Pharmaceuticals LLC | $127.66 | 2024-2025 | Provenge |
| Medtronic USA, INC. | $125.01 | 2019 | |
| Pfizer INC. | $110.20 | 2025 | |
| Palette Life Sciences, INC. | $91.50 | 2022 | |
| Merck Sharp & Dohme LLC | $86.44 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $81.87 | 2024-2025 | Injectafer, Enhertu |
| Abbvie INC. | $77.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.34 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $67.03 | 2025 | Iclusig |
| Jazz Pharmaceuticals INC. | $65.40 | 2025 | |
| Genentech USA, INC. | $62.20 | 2022-2025 | Itovebi, Tecentriq |
| Geron Corporation | $59.30 | 2025 | Rytelo |
| Progenics Pharmaceuticals, INC. | $47.15 | 2024-2025 | |
| Array Biopharma INC | $46.29 | 2025 | Lorbrena, Xalkori, Mektovi |
| Exelixis INC. | $46.21 | 2024-2025 | Cabometyx |
| Incyte Corporation | $41.46 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.87 | 2024-2025 | Gilotrif |
| Beigene USA, INC. | $38.01 | 2025 | Tevimbra, Brukinsa |
| Agios Pharmaceuticals, INC. | $36.15 | 2024-2025 | Pyrukynd |
| Tersera Therapeutics LLC | $31.25 | 2025 | Quzyttir |
| Rigel Pharmaceuticals, INC. | $29.23 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Iovance Biotherapeutics, INC. | $29.13 | 2025 | Amtagvi |
| Sumitomo Pharma America, INC. | $28.90 | 2023-2025 | Orgovyx |
| Lilly USA, LLC | $25.41 | 2025 | Verzenio |
| Mirati Therapeutics, INC. | $22.39 | 2024 | Krazati |
| Eisai INC. | $21.73 | 2025 | |
| Myovant Sciences INC. | $21.32 | 2022 | |
| Beone Medicines USA, INC. | $19.91 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $19.44 | 2024 | |
| Astellas Pharma US INC | $18.64 | 2025 | Vyloy |
| Bioprotect Medical, INC. | $17.74 | 2025 | Bioprotect Balloon Implant System |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.38 | 2024 | Oxlumo |
| Kobold, LLC | $2.00 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$133,308.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.